Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.4043
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 211202733300.0
- FreeCF/Share 6.7321
- PFCF 12.3953
- PE 12.2108
- Debt/Assets 0.3027
- DivYield 0.038
- ROE 0.3816
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
Read More
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.
Read More
Merck Announces Fourth-Quarter 2025 Dividend
Published: July 22, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter 2025 Dividend.
Read More
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.
Read More
Does This Move Make Merck Stock a Buy?
Published: July 20, 2025 by: The Motley Fool
Sentiment: Neutral
Merck (MRK -1.91%), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous cancer medicine.
Read More
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Published: July 20, 2025 by: The Motley Fool
Sentiment: Positive
One of the big reasons to like Pfizer (PFE -0.47%) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock a bit over 1.7%.
Read More
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: July 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Read More
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
Read More
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
Read More
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Read More
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Read More
Major deals involving U.S. drugmakers and biotechs over the past decade
Published: July 09, 2025 by: Reuters
Sentiment: Positive
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Read More
Undercovered Dozen: Roku, Merck, Chevron And More
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, INMune Bio, Nutex Health, LyondellBasell, Shopify, IBIT:CA and BITO are rated Strong Buy or Buy. MSTY is rated Hold.
Read More
Merck to Buy Verona Pharma for Around $10 Billion
Published: July 09, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Read More
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
Published: July 09, 2025 by: Schwab Network
Sentiment: Positive
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Read More
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Read More
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
Published: July 09, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Read More
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Published: July 09, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
Read More
Merck & Co.: A Pharma Titan At A Discount
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its current market price, MRK is as much as 23% undervalued. Underlying fundamentals are still strong, with great margins, heavy R&D investing, and a plan to aggressively expand by CapEx spending totaling $20 billion from 2024 to 2028.
Read More
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
Read More
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Read More
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Read More
Top 10 High-Yield Dividend Stocks For July 2025
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performing in-line with SPY and VYM, while providing a superior dividend yield. The June 2025 watchlist includes 10 stocks with an average forward dividend yield of 3.54% and an expected return of 13.62%.
Read More
Dividend Yield Theory Says Merck Is A Buy
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expiration and political headwinds, Merck's robust pipeline and adaptability offer a credible path to future growth. DYT analysis projects a 42%-83% total return over four years, with Merck meeting or exceeding most fundamental quality metrics.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000